NCT01453920View on ClinicalTrials.gov

Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing

PHASE4CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Age Related Macular Degeneration
Interventions
DRUG

Ranibizumab

Intravitreal Ranibizumab 0.05cc (10mg/ml)

DRUG

Ranibizumab

Intravitreal Ranibizumab 0.05cc (10mg/ml)

Trial Locations (1)

M5T 2S8

Toronto Western Hospital, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT01453920 - Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing | Biotech Hunter | Biotech Hunter